These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31583613)

  • 21. Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children.
    Zhou W; Johnson TN; Bui KH; Cheung SYA; Li J; Xu H; Al-Huniti N; Zhou D
    Clin Pharmacol Ther; 2018 Jul; 104(1):188-200. PubMed ID: 29027194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytochrome P450 1A2 Messenger RNA is a More Reliable Marker than Cytochrome P450 1A2 Activity, Phenacetin O-Deethylation, for Assessment of Induction Potential of Drug-Metabolizing Enzymes Using HepaRG Cells.
    Ogasawara A; Kato N; Torimoto N; Aohara F; Ohashi R; Yamada Y; Taniguchi H
    Drug Metab Lett; 2018; 12(1):14-23. PubMed ID: 29357810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. WB-PBPK approach in predicting zidovudine pharmacokinetics in preterm neonates.
    Wei L; Mansoor N; Khan RA; Czejka M; Ahmad T; Ahmed M; Ali M; Yang DH
    Biopharm Drug Dispos; 2019 Nov; 40(9):341-349. PubMed ID: 31693190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gestation-Specific Changes in the Anatomy and Physiology of Healthy Pregnant Women: An Extended Repository of Model Parameters for Physiologically Based Pharmacokinetic Modeling in Pregnancy.
    Dallmann A; Ince I; Meyer M; Willmann S; Eissing T; Hempel G
    Clin Pharmacokinet; 2017 Nov; 56(11):1303-1330. PubMed ID: 28401479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Renal Impairment Influence on Metabolic Drug Clearance using a Modelling Approach.
    Tuloup V; Goutelle S; Tod M; Bourguignon L
    Clin Pharmacokinet; 2023 Feb; 62(2):307-319. PubMed ID: 36631686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation.
    Ohyama K; Murayama N; Shimizu M; Yamazaki H
    Xenobiotica; 2014 Jan; 44(1):10-6. PubMed ID: 23777257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone.
    Shou M; Korzekwa KR; Brooks EN; Krausz KW; Gonzalez FJ; Gelboin HV
    Carcinogenesis; 1997 Jan; 18(1):207-14. PubMed ID: 9054608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of a physiologically based pharmacokinetic model for rats to study the influence of body fat mass and induction of CYP1A2 on the pharmacokinetics of TCDD.
    Emond C; Birnbaum LS; DeVito MJ
    Environ Health Perspect; 2006 Sep; 114(9):1394-400. PubMed ID: 16966094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physiologically based pharmacokinetic modelling of acetaminophen in preterm neonates-The impact of metabolising enzyme ontogeny and reduced cardiac output.
    Olafuyi O; Abbasi MY; Allegaert K
    Biopharm Drug Dispos; 2021 Nov; 42(9):401-417. PubMed ID: 34407204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
    Fenneteau F; Poulin P; Nekka F
    J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes.
    Potęga A; Fedejko-Kap B; Mazerska Z
    Pharmacol Rep; 2016 Aug; 68(4):663-70. PubMed ID: 27110874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age-Related Changes in Pediatric Physiology: Quantitative Analysis of Organ Weights and Blood Flows : Age-Related Changes in Pediatric Physiology.
    Chang HP; Kim SJ; Wu D; Shah K; Shah DK
    AAPS J; 2021 Mar; 23(3):50. PubMed ID: 33791883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes.
    Stader F; Siccardi M; Battegay M; Kinvig H; Penny MA; Marzolini C
    Clin Pharmacokinet; 2019 Apr; 58(4):483-501. PubMed ID: 30128967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam.
    Britz H; Hanke N; Volz AK; Spigset O; Schwab M; Eissing T; Wendl T; Frechen S; Lehr T
    CPT Pharmacometrics Syst Pharmacol; 2019 May; 8(5):296-307. PubMed ID: 30762305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and evaluation of a generic physiologically based pharmacokinetic model for children.
    Edginton AN; Schmitt W; Willmann S
    Clin Pharmacokinet; 2006; 45(10):1013-34. PubMed ID: 16984214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
    Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
    Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of Clearance and Dose of Midazolam in Preterm and Term Neonates: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling.
    Mansoor N; Ahmad T; Alam Khan R; Sharib SM; Mahmood I
    Am J Ther; 2019; 26(1):e32-e37. PubMed ID: 27574923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
    Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
    Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes.
    Masubuchi Y; Horie T
    Chem Res Toxicol; 1999 Oct; 12(10):1028-32. PubMed ID: 10525281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The inhibitory activity of the extracts of popular medicinal herbs on CYP1A2, 2C9, 2C19 and 3A4 and the implications for herb-drug interaction.
    Fasinu PS; Bouic PJ; Rosenkranz B
    Afr J Tradit Complement Altern Med; 2014; 11(4):54-61. PubMed ID: 25392581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.